The appointment follows the resignation of Andrew Wood as CFO. He will continue as an employee of the company for the immediate future to ensure a successful transition.
Tim Watts has over 30 years’ experience as a financial executive, and has worked within the pharma industry for the last 21 years. His areas of expertise include managing corporate transactions, M&A activity, fundraising and strategic implementation.
With a background in accountancy, Watts joined the pharmaceuticals division of ICI in 1990 and rose to become Finance Director of Zeneca Pharmaceuticals. Following the company’s merger with Astra, he became Group Financial Controller of AstraZeneca in 2001 before leaving to become CFO of Archimedes Pharma.
John Dawson, CEO of Oxford BioMedica, said: “We thank Andrew for his substantial contribution to Oxford BioMedica since its IPO in 1996. His commitment to the Company has been invaluable. I would like to welcome Tim to the executive management team and am confident that his expertise will support Oxford BioMedica’s strategy to secure corporate and commercial success.”
Oxford BioMedica develops gene-based medicines and therapeutic vaccines aimed at addressing serious unmet medical needs. The company’s current partners and licensees include Sanofi, Pfizer, GSK and Biogen Idec.